Telisotuzumab vedotin
- telisotuzumab vedotin An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity.
Mechanism of action of Telisotuzumab vedotin[edit source]
Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.
Clinical Trials Using Telisotuzumab vedotin[edit source]
Check for ACTIVE CLINICAL TRIALS
| Telisotuzumab vedotin Resources | ||
|---|---|---|
|
| |
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
